Compare Thomson Reuters Corp (TRI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Twist Bioscience Corp — how do they compare? Thomson Reuters Corp trades at $97 (market cap $42.75B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Thomson Reuters Corp is far larger — about 5.1× Twist Bioscience Corp's market cap, and Thomson Reuters Corp pays a 2.65% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TRI | TWST | |
|---|---|---|
Market Cap | $42.75B | $8.42B |
Sector | Industrials | Health |
52-Week High | $173.48 | $153.10 |
52-Week Low | $76.55 | $24.16 |
Enterprise Value | $45.37B | $8.35B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $98.81, down 6.5% in 24 hours, with a bearish technical signal and support near $97. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Revenue grew 9% organically, with strong performance in Legal, Corporates, and Tax segments. Net income margin is 21.22%, and the P/E ratio is 26.03. Recent news highlights AI expansion with the launch of the proprietary Thomson-1 LLM and a cybersecurity incident affecting its case management system.
Outlook is mixed: robust recurring revenue and AI adoption support growth, but the stock faces near-term pressure from the price drop and cybersecurity risks. Analysts maintain a buy consensus with a $113 price target, implying 14% upside. Key risks include execution on AI initiatives, competitive pressures, and potential fallout from the security breach.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
